Eva Decroli
Endocrinology And Metabolic Subdivision, Division Of Internal Medicine, Dr. M. Djamil General Hospital/ Medical Faculty Of Andalas University, Padang, West Sumatera, Indonesia

Published : 43 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : INDONESIAN JOURNAL OF PHARMACY

The Effect of Thionamide to TRH, TSH, IL-4, T-REG, and Anti-TPO in Graves’ Disease Eva Decroli; Dwitya Elvira; Dinda Aprilia
Indonesian Journal of Pharmacy Vol 30 No 2, 2019
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (774.604 KB) | DOI: 10.14499/indonesianjpharm30iss2pp122-127

Abstract

The most common cause of hyperthyroidism is Graves' disease. TRH and TSH are hormonal factors that modulate and control thyroid function in Graves' disease. In the immunological aspect, Graves' disease is played by the role of T-reg, IL-4, and anti-TPO. Graves' disease treatment goal is to inhibit thyroid hormone secretion by administering thionamide. The evaluation of this treatment is its hormonal and immunological aspects. To describe the effect of thionamide on serum TRH, TSH, IL-4, T-reg, and anti-TPO levels in Graves' disease. This study is a clinical trial study in 25 study participants. All study participants were given thionamide, namely PTU 300mg for three months and blood samples were taken for laboratory tests. Serum TRH, TSH, IL-4, T-reg FOXP3, and anti-TPO levels were examined by ELISA. The mean levels at the beginning and after three months of therapy are: serum TRH 92.589pg/mL and 115.944pg/mL; serum TSH 0.041mU/L and 0.223mU/L; serum IL-4 19.759pg/mL and 23.040pg/mL; T-reg FOXP3 gene polymorphism 0.621ng/mL and 0.518 ng/mL; serum anti-TPO 2697.539pg/mL and 2604.710pg/mL. Increased levels of serum TRH and TSH levels were statistically significant. The change in serum IL-4, T-reg FOXP3 gene polymorphism, and anti-TPO levels were not statistically significant. The administration of thionamide in Graves' disease for three months will significantly decrease Wayne index and serum FT4 levels, increase serum TRH and TSH levels.
Co-Authors Adang Bachtiar Ade Chandra Afriwardi Afriwardi Ahmad, Armen Al Hafiz Alexander Kam Alexander Kam Alfitri, Maura Salsabila Andi Fadilah Yusran Putri Antoni, Adi Aprilia, Dinda Asman Manaf Aulia, Salsabila Syafna Auliangi Tamayo Brian Sri Prahastuti Darwin Amir, Darwin Deddy Saputra Delmi Sulastri Dessy Arisanty Dinda Aprilia Dinda Aprilia Dwitya Elvira, Dwitya Efendi, Nursyirwan Efendi, Yanne Pradwi Ellyza Nasrul Eryati Darwin Eti Yerizel Fadella, Annesa Fadrian, Fadrian Fahrurozi, R. Ifan A. Fauzar Fauzar Finisia Noviyanti Firdawati Firdawati Garri Prima Decroli Genta Pradana, Genta Hafni Bachtiar Hardisman Harie Satria ES Husna Yetti Jannah, Lidya Raudhatul Kam, Alexander Linosefa Linosefa Martini, Rose D Meliza Wahyuni Mudjiran Muhammad Luthfi Muharramah, Disa Hijratul Murni, Arina W Mustafa Noer Muthia Faurin Mutia Lailani Nada Utami Prahastiwi Nadila Andam Astari Namanda Putri, Athari Fadhila Nining Kurniawati Nur Indrawati Lipoeto Nurhayati Nurhayati Prayitno, Irwan Putri Sri Lasmini Putri, Biomechy Oktomalio Putri, Septia Harma Putri, Vidola Yasena Rahayuningsih, Sri Puji Restu Susanti Risviani, Darayani Ritonga, Sukhri Herianto Robby Satria Putra Roza Kurniati Roza Mulyana Saptino Miro Saptino Miro, Saptino Sheila Jihan Safira Sofiani, Dinda Putri Sukri Rahman Susila Sastri Syafril Syahbuddin Syafril Syahbuddin Tamayo, Auliangi Try Rahmi Lussii Karsuita Ulvyana, Vyora Viotra, Deka Yanne Pradwi Efendi Yoga, Vesri Yulia, Dwi Yuliarni Syafrita Yusrawati Yusrawati Yustini Alioes Zelly Dia Rofinda